Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
INCY • Stock • Health Care / Biotechnology
Current Price
$115.30
-1.57%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
INCY's evidence points supportive across the available windows.
Generated 2026-10-05T11:30:00.000Z • Evidence 302c7671
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
5
Opposing articles
0
Neutral articles
10
Confidence basis
Supporting evidence
• Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience
• Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
• Incyte Stock: Is Wall Street Bullish or Bearish?
• Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
• Incyte Sales Growth Drives Share Price Gains
Opposing evidence
No opposing articles were found in this window.
Catalysts
• Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience
• Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
• HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
• Incyte Stock: Is Wall Street Bullish or Bearish?
• Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
Risks
No specific risk mentions were identified in this window.
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (5) grows relative to opposing evidence (0) in this window.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (5) in this window.
Showing 8 of 15 sources
Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience
ChartMill • 2026-08-27 • Bullish
Open via Finnhub →Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Benzinga • 2026-08-20 • Neutral
Open via Finnhub →HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
Benzinga • 2026-08-20 • Neutral
Open via Finnhub →Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Benzinga • 2026-08-20 • Bullish
Open via Finnhub →Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
ChartMill • 2026-08-17 • Bullish
Open via Finnhub →Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Benzinga • 2026-08-17 • Neutral
Open via Finnhub →Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
Yahoo • 2026-08-14 • Neutral
Open via Finnhub →